Startups
Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas.
With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.
With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.
Overview
Location
United States, Georgia, Suwanee
Employees
11-50
Total raised
$50.2M
Founded date
2004
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Apr 30, 2015 | Series B round | $10.2M |
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 11, 2024 | Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market | Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women’s reproductive healthcare products ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical co... |
| Sep 11, 2024 | Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market | ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therape... |
| Jun 17, 2024 | 'Don't Just Give Out the Work -- Do the Work': How This Women's Healthcare CEO Leads With Passion Kathy Lee-Sepsick, CEO of Femasys, emphasizes preparedness, balance, and self-care as the core of visionary leadership. | On this episode of "The Founder CEO," we spoke with Kathy Lee-Sepsick, founder and CEO of Femasys, who shared her personal motivation for starting the company. Driven by her own experiences, she saw a dire need for better options ... |
| Mar 13, 2024 | Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 | |
| Mar 6, 2024 | Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution | |
| Feb 25, 2022 | Tillman Gerngross leads a pack of biotech CEOs out the door; With eyes on pipeline expansion, Poseida woos a gene therapy exec from Novartis | Tillman Gerngross As market volatility sweeps through the landscape, CEO changes are really ramping up, and topping the list is Tillman Gerngross, a force in the antibody space who hitched his wagon to finding another Covid-19 solution by c... |
| Jun 21, 2021 | FEMASYS INC. Chardan : Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO | NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY) a biomedical company focuse... |
| Dec 20, 2016 | Femasys Raises $40M Series C Round | ATLANTA, GA, Femasys, a developer of innovative medical devices for the women's healthcare market, today announced that it has closed $40 million in Series C financing. >> Click here for more funding data on Femasys >> To ex... |
| Dec 20, 2016 | Term Sheet — Monday, December 19 | THE TRUMP CONUNDRUM The following column appears in the latest issue of Fortune. (View online version here.) Paid Content What you need to know about growing cyberattacks From ExtraHop It was a potent sentiment shared throughout the tech in... |
Show more
Reviews 0
FAQ about Femasys
When was Femasys founded?
Femasys was founded in 2004.
How much funding has Femasys raised?
Femasys has raised $50.2M in total across 2 funding rounds.
What funding rounds has Femasys raised?
Parsers VC lists 2 funding rounds of Femasys, among them a Series B round of $10.2M on Apr 30, 2015.
What has the press written about Femasys?
Parsers VC has collected 15 articles mentioning Femasys, among them “Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market” (Sep 11, 2024) and “Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market” (Sep 11, 2024).
Is Femasys still active?
Yes, Femasys is active; its latest activity on Parsers VC dates from Sep 2, 2025.